Your browser is no longer supported. Please, upgrade your browser.
Settings
RYTM Rhythm Pharmaceuticals, Inc. daily Stock Chart
RYTM [NASD]
Rhythm Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.97 Insider Own1.80% Shs Outstand33.19M Perf Week-9.51%
Market Cap985.08M Forward P/E- EPS next Y-2.56 Insider Trans- Shs Float28.60M Perf Month-9.84%
Income-52.90M PEG- EPS next Q-0.49 Inst Own72.30% Short Float2.30% Perf Quarter-0.54%
Sales- P/S- EPS this Y-150.30% Inst Trans-2.11% Short Ratio2.34 Perf Half Y18.06%
Book/sh10.17 P/B2.92 EPS next Y-24.00% ROA-34.30% Target Price39.00 Perf Year-
Cash/sh8.67 P/C3.43 EPS next 5Y20.70% ROE-41.40% 52W Range16.80 - 37.23 Perf YTD2.13%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-20.28% Beta-
Dividend %- Quick Ratio40.10 Sales past 5Y- Gross Margin- 52W Low76.67% ATR1.69
Employees26 Current Ratio40.10 Sales Q/Q- Oper. Margin- RSI (14)39.97 Volatility6.87% 5.25%
OptionableNo Debt/Eq0.00 EPS Q/Q-65.40% Profit Margin- Rel Volume0.26 Prev Close31.88
ShortableYes LT Debt/Eq0.00 EarningsAug 13 BMO Payout- Avg Volume281.43K Price29.68
Recom1.70 SMA20-6.20% SMA50-8.16% SMA2006.82% Volume73,929 Change-6.90%
Jun-25-18Reiterated Needham Buy $36 → $42
Jun-15-18Reiterated Needham Buy $32 → $36
Oct-30-17Initiated Needham Buy $32
Oct-30-17Initiated BofA/Merrill Buy $30
Aug-08-18 04:01PM  Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-23-18 08:00AM  Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity GlobeNewswire
Jun-25-18 04:01PM  Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Jun-21-18 03:31PM  Here's Why Rhythm Pharmaceuticals Inc Rose as Much as 37% Today Motley Fool +24.56%
Jun-20-18 09:37PM  Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering GlobeNewswire
Jun-18-18 05:19PM  Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering GlobeNewswire -11.66%
07:00AM  Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity GlobeNewswire
Jun-14-18 08:00AM  Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity GlobeNewswire
Jun-05-18 07:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within BiondVax Pharmaceuticals, MercadoLibre, 1-800 FLOWERS.COM, Redhill Biopharma, Mountain Province Diamonds, and Rhythm Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Jun-04-18 09:41AM  The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals Zacks
Jun-01-18 08:00AM  Rhythm Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference GlobeNewswire
May-31-18 06:45AM  Will Rhythm Pharmaceuticals (RYTM) Continue to Surge Higher? Zacks
May-14-18 08:00AM  Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results GlobeNewswire +12.83%
May-09-18 04:01PM  Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire
04:01PM  Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity GlobeNewswire
Apr-11-18 07:40AM  Consolidated Research: 2018 Summary Expectations for Ctrip.com International, JA Solar Holdings, Co., Oaktree Specialty Lending, Rhythm Pharmaceuticals, Cellectis S.A, and Travelport Worldwide Fundamental Analysis, Key Performance Indications GlobeNewswire
Apr-02-18 08:00AM  Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome GlobeNewswire -14.47%
Mar-19-18 04:01PM  Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018 GlobeNewswire
Mar-15-18 08:15AM  Report: Exploring Fundamental Drivers Behind Reading International, Rhythm Pharmaceuticals, Grupo Aeroportuario del Centro Norte S.A.B. de C.V., Golar LNG, Central European Media Enterprises, and MediciNova New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -10.89%
Mar-12-18 04:01PM  Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Mar-07-18 04:01PM  Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March GlobeNewswire
Jan-09-18 09:00AM  WuXi NextCODE Artificial Intelligence Used to Advance Precision Therapy for Rare Genetic Disorders of Obesity PR Newswire -5.53%
Jan-04-18 08:00AM  Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity GlobeNewswire
Nov-14-17 08:00AM  Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results GlobeNewswire -5.66%
07:00AM  Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team PR Newswire
Nov-13-17 10:00AM  Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire +5.16%
Nov-02-17 07:20AM  Two Boston-area biotechs raise combined $152M in IPOs American City Business Journals -7.70%
Oct-31-17 08:01AM  Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome GlobeNewswire
Oct-10-17 04:13PM  This Company Gained 76% in its IPO -- and It Isn't Even a Tech Company Motley Fool +5.86%
04:01PM  Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Oct-08-17 08:41AM  IPO News This Week: Online Auto Marketplace, CarGurus, Tops the List 24/7 Wall St.
Oct-06-17 11:45AM  Switch Keeps Recent IPO Market Momentum Going Benzinga -15.83%
Oct-04-17 09:09PM  Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering GlobeNewswire
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alstrom syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals, Inc. is a subsidiary of Motus Therapeutics, Inc.